(Q43460357)

English

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics

scientific article published on 14 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

based on heuristic

inferred from title

7

object named as

Vural Ozdemir

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

Yutaro Suzuki

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Takuro Sugai

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Naoki Fukui

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Junzo Watanabe

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Shin Ono

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Yoshimasa Inoue

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Toshiyuki Someya

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

language of work or name

0 references

publication date

14 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

908-914

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Given the complexity of the human genome, can 'personalised medicine' or 'individualised drug therapy' ever be achieved?

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Personalized Medicine Beyond Genomics: New Technologies, Global Health Diplomacy and Anticipatory Governance

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

1 reference

https://api.crossref.org/works/10.1177%2F0269881110370504

21 January 2018

Identifiers

10.1177/0269881110370504

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43460357&oldid=1989208578"